Disc Medicine Statistics
Total Valuation
Disc Medicine has a market cap or net worth of $2.29 billion. The enterprise value is $1.52 billion.
Important Dates
The last earnings date was Thursday, February 26, 2026, before market open.
| Earnings Date | Feb 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Disc Medicine has 38.16 million shares outstanding. The number of shares has increased by 27.86% in one year.
| Current Share Class | 38.16M |
| Shares Outstanding | 38.16M |
| Shares Change (YoY) | +27.86% |
| Shares Change (QoQ) | +6.98% |
| Owned by Insiders (%) | 1.25% |
| Owned by Institutions (%) | 98.09% |
| Float | 32.89M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.06 |
| P/TBV Ratio | 3.08 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 21.94, with a Debt / Equity ratio of 0.04.
| Current Ratio | 21.94 |
| Quick Ratio | 21.59 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -65.20 |
Financial Efficiency
Return on equity (ROE) is -35.86% and return on invested capital (ROIC) is -23.62%.
| Return on Equity (ROE) | -35.86% |
| Return on Assets (ROA) | -22.55% |
| Return on Invested Capital (ROIC) | -23.62% |
| Return on Capital Employed (ROCE) | -30.53% |
| Weighted Average Cost of Capital (WACC) | 18.75% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.37M |
| Employee Count | 155 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Disc Medicine has paid $361,000 in taxes.
| Income Tax | 361,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +10.89% in the last 52 weeks. The beta is 2.66, so Disc Medicine's price volatility has been higher than the market average.
| Beta (5Y) | 2.66 |
| 52-Week Price Change | +10.89% |
| 50-Day Moving Average | 72.08 |
| 200-Day Moving Average | 69.38 |
| Relative Strength Index (RSI) | 38.48 |
| Average Volume (20 Days) | 1,058,949 |
Short Selling Information
The latest short interest is 4.27 million, so 11.19% of the outstanding shares have been sold short.
| Short Interest | 4.27M |
| Short Previous Month | 3.41M |
| Short % of Shares Out | 11.19% |
| Short % of Float | 12.98% |
| Short Ratio (days to cover) | 4.72 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -235.17M |
| Pretax Income | -211.82M |
| Net Income | -212.18M |
| EBITDA | -234.89M |
| EBIT | -235.17M |
| Earnings Per Share (EPS) | -$6.01 |
Full Income StatementBalance Sheet
The company has $791.15 million in cash and $31.02 million in debt, with a net cash position of $760.13 million or $19.92 per share.
| Cash & Cash Equivalents | 791.15M |
| Total Debt | 31.02M |
| Net Cash | 760.13M |
| Net Cash Per Share | $19.92 |
| Equity (Book Value) | 739.83M |
| Book Value Per Share | 19.53 |
| Working Capital | 767.26M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$180.39 million and capital expenditures -$933,000, giving a free cash flow of -$181.33 million.
| Operating Cash Flow | -180.39M |
| Capital Expenditures | -933,000 |
| Free Cash Flow | -181.33M |
| FCF Per Share | -$4.75 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Disc Medicine does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -27.86% |
| Shareholder Yield | -27.86% |
| Earnings Yield | -9.30% |
| FCF Yield | -7.95% |
Analyst Forecast
The average price target for Disc Medicine is $101.67, which is 69.08% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $101.67 |
| Price Target Difference | 69.08% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
